The role of thyroxine in the control of serum cholesterol has long been recognized clinically. In hypothyroidism hypercholesteremia assumes some diagnostic importance; whereas, a tendency to hypocholesteremia is often recorded in hyperthyroidism. The administration of desiccated thyroid and thyroid extracts will reduce the serum cholesterol and phospholipid.1
At the present time a rather voluminous literature points to the probability that elevated lipids constitute one of the factors involved in atherogenesis. Therefore, if thyroxine could be altered so as to maintain its cholesterol-lowering effect without altering general body metabolism a useful research and possible therapeutic tool would be available. It is the purpose of this paper to present a clinical experience with one of these thyroxine analogues.
Tetraiodothyroformic acid (TFA-4) is formulated by substituting a carboxyl group for the alanine side-chain of thyroxine (Fig. 1). Duncan and Best2-4 studied this compound in rats and found that, when compared to
LOVE VL. Effect of Thyroxine Analogue TFA-4 on Serum Cholesterol. Arch Intern Med. 1961;108(6):833–836. doi:10.1001/archinte.1961.03620120017003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: